

#### **NEWSLETTER**

### YISSUM INNOVATION



As we approach the Jewish New Year, I reflect on the past and promises of the future. It's a time of renewal, a time to highlight the achievements that have brought us to this moment and to set our sights higher.

After approximately 15 years at Yissum, including over five years as CEO, I have decided to look for my next challenge. It has been a privilege to advance groundbreaking research towards commercialization and support Hebrew University as a leader in the tech industry. Together with a wonderful team at Yissum, we have invested our efforts to serve as a bridge connecting technologies that will create a better world.

As we conclude our 60th year, I am proud to share that under my leadership, we signed hundreds of commercial and research agreements, leading to the establishment of over forty new companies.

Our most recent companies include:

- Qedma has partnered with IBM, introducing its Quantum Error Suppression and Error Mitigation (QESEM) solution as part of IBM's Qiskit Functions.
- Cultivo by Professor Ofra Benny, whose investor, Fresh-start, is supporting the technology in its mission with edible biosymbiotic ex-vivo cultures.
- Naya, developed by Professor Ofer Mandelboim, focuses on antibodies that can block NKp46. This approach aims to reduce harmful immune responses in conditions where the immune system mistakenly attacks healthy cells, while being cautious of its role in fighting infections and cancer.
- BioArmix, a portfolio company based on technology of Professor Amos Nussinovitch and Prof. Edouard Jurkevitch has created predatory beads helping against potato soft rot. The Galil Ofek Incubator is facilitating in the establishment.

In the words of Albert Einstein, "The value of achievement lies in the achieving." Together, we are stronger and act as one, especially in thanks to our partners.

As we look forward to seeing what comes of these new partnerships, there's both optimism and determination to make a meaningful impact on the world.

Wishing everyone a prosperous, meaningful New Year and fruitful beginnings,



## HIGHLIGHTING NEW PARTNERSHIPS



#### THE NEXT GENERATION CANCER TEST

Salignostics, a member of the ARC Innovation and Sheba Medical Center, Tel Hashomer, have joined forces to develop a revolutionary test for early detection of oral cancer through saliva analysis.

#### >> Read more here



#### IN MEAT WE TRUST

Believer Meats has partnered with the Bezos Center for Sustainable Protein at NC State University to advance alternative protein production, backed by a \$30 million grant. This partnership combines innovation and commercialization to meet global protein demands.



#### PLURI AND WILK TO CHANGE MILK PRODUCTION

A novel food solution for the elderly: human breast milk-derived on a commercial scale. With a rapidly growing elderly population, breast milk produced from cells will improve the quality of life for millions.

#### >> Read more here



#### **OEDMA AND IBM PROVIDE SOLUTIONS**

Qedma's QESEM solution, now part of IBM's Qiskit, improves quantum computing reliability by reducing errors without extra qubits, aiming to accelerate quantum advantage.

#### **>>>>**

### **AWARDS**



#### ORSIGHT ACHIEVES RECOGNITION

Orsight Pharma Ltd. has been selected as a grant recipient by the Israel Innovation Authority, marking a significant milestone in highlighting their dedication to pioneering eye disease treatments.



#### KAYE PRIZE 2024 CELEBRATES IMPACT

Yissum presented the Isaac Kaye Award to Prof. Yossi Tam for obesity research, Prof. Ofra Benny for cancer research, Prof. Zvi Peleg for AgTech advancements, and Ph.D. student Tomer Babu for innovations in cancer treatment.



#### HYDROGEN TO SUPPLY NEW ENERGY

Hydro X won the Silver Award for Disruptive Technology of Hydrogen Storage at this year's TERA-Award for their "Reshaping H2 Storage and Transportation" project. Their technology enables safe, cost-effective hydrogen storage and transport at under \$1 per kilogram.




#### ASPER PRIZE WITH YISSUM AND HUJI INNOVATE

GynTools and Hydro X awarded 2024 ASPER-HUJI Innovate Rising Startups of the Year for advancing women's healthcare and hydrogen storage.

#### **>>>>**

# SUPPORT NEW TECHNOLOGIES



#### **NEW DRUG TO FIGHT INFECTIONS**

Prof. Zvi Hayouka has created special molecules that fight bacteria, even those resistant to antibiotics. These molecules can deliver drugs directly to infection sites, boosting antibiotic effectiveness. This could significantly help combat antibiotic resistance and save lives. >> Read more here



#### THE FUTURE OF COMMUNICATION

Prof. Yossi Adi is building the first collection of Modern Hebrew spoken words and sentences, along with written transcriptions, to help develop systems that can recognize, model, and create Hebrew speech.

>> Read more here



#### PROBIOTICS AS A CURE FOR LIVER

A new probiotic is being developed by Prof. Oren Tirosh to overexpress and secrete ADH4 enzymes to protect from diet-induced obesity, metabolic impairment and irritable bowel syndrome. This technology can help millions suffering from chronic conditions.

>> Read more here



#### TARGETED NANOPARTICLES FOR NAFLD THERAPY

Prof. Yossi Tam's technology uses nanoparticles to deliver a previously abandoned CB1R blocker, Rimonabant, directly to the liver to treat non-alcoholic fatty liver disease (NAFLD). This method avoids the drug's harmful side effects.

>> Read more here

## UPCOMING WEBINAR



November 19th, 2024 12 Noon EST I 7 pm IST Click to Register



We invite you to an exclusive webinar highlighting groundbreaking research from the Hebrew University's chemical biology laboratory. Despite the challenges posed by the ongoing conflict in Israel, HUJI remains dedicated to advancing science and discovering innovative treatments. This event will feature Dr. Raphael Benhamou, who will present his pioneering work on RNA-targeted therapies.

An Assistant Professor at HU's School of Pharmacy, Dr. Raphael Benhamou has led cutting-edge research since 2021. His previous experience includes post-doctoral research at Scripps Research Institute, where he focused on designing small molecules targeting RNAs. Dr. Benhamou focuses on the role of RNA in disease, using organic chemistry to create small molecules that bind to and modify specific RNA motifs. These molecules function as both probes for studying RNA complexes and potential drugs for treating diseases ranging from cancer to infectious diseases.

The webinar will offer an insightful presentation by Dr. Benhamou, providing an opportunity to explore the latest advancements in RNA-targeted therapies. Attendees will learn about the potential new treatments for various diseases and have the chance to engage with Dr. Benhamou during a Q&A session. Please join us in supporting the ongoing efforts of our dedicated researchers and gain valuable insights into the future of medical treatments. We look forward to your participation.

YISSUM, THE HEBREW UNIVERSITY TECH TRANSFER HI-TECH PARK, EDMOND J. SAFRA CAMPUS, BUNGALOW 2.6 GIVAT-RAM, JERUSALEM P.O. BOX 39135 91390 ISRAEL I WEBSITE: YISSUM.CO.IL





